RA-ILD: Tracking Function and CT
Conventional monitoring markers do not change before deaths in this predominantly mild cohort.
-
By
-
Kathryn Wighton
-
March 6, 2026
-
Clinical Scorecard: RA-ILD: Tracking Function and CT
At a Glance
| Category | Detail |
|---|
| Condition | Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD) |
| Key Mechanisms | Pulmonary fibrosis characterized by traction bronchiectasis and/or honeycombing on high-resolution CT. |
| Target Population | Adult patients with rheumatoid arthritis meeting ACR criteria and confirmed ILD on CT. |
| Care Setting | Rheumatology clinics in Brazil. |
Key Highlights
- Stable pulmonary function and imaging measures over 24 months.
- 8% mortality rate observed, with deaths not preceded by measurable decline in FVC.
- 80% of patients had pulmonary fibrosis, but only 20% classified as definite/probable usual interstitial pneumonia.
- Densitometry-based CT measures showed no meaningful longitudinal change.
- 12% of patients improved, 69% remained stable, and 19% worsened at 24 months.
Guideline-Based Recommendations
Diagnosis
- Confirm ILD via high-resolution CT in patients meeting ACR criteria for RA.
Management
- Monitor pulmonary function tests and imaging at baseline, 12, and 24 months.
Monitoring & Follow-up
- Assess FVC, 6-minute walk distance, and quality-of-life at specified intervals.
Risks
- Mortality may occur without preceding functional decline or imaging progression.
Patient & Prescribing Data
105 enrolled patients with RA-ILD, mean age 63 years, 81% female.
No lung transplantations occurred; deaths were often associated with pulmonary infections.
Clinical Best Practices
- Utilize a centralized qualitative imaging review for consistency.
- Consider the stability of pulmonary function in management decisions.
- Recognize the potential for mortality without prior functional decline.
Related Resources & Content
